Atrial fibrillation and the expanding role of catheter ablation: Do antiarrhythmic drugs have a future?

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The main therapeutic strategies for treating atrial fibrillation include rate control, maintenance of sinus rhythm, and antiembolic treatment. Current antiarrhythmic drugs are effective in about 50% of patients and are often associated with adverse effects. Multiple trials suggest that rate control with proper anticoagulation treatment is associated with a similar prognosis to a more aggressive rhythm control strategy. Catheter ablation of atrial fibrillation has success rates that exceed currently available antiarrhythmic drugs. However, catheter ablation is an evolving technique that can result in complications. In some patients, antiarrhythmic drugs are still required following ablation. New antiarrhythmic drug strategies include developing drugs that are more atrial selective, alteration of the multichannel blocking agent, amiodarone, or the development of drugs with novel mechanisms of action such as gap junction facilitation of conduction. Although catheter ablation procedures will continue to grow, the millions of atrial fibrillation patients who will require therapy will continue to make antiarrhythmic drug therapy an important part of our ongoing therapeutic armamentarium.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2008

Fingerprint

Catheter Ablation
Anti-Arrhythmia Agents
Atrial Fibrillation
Therapeutics
Amiodarone
Gap Junctions
Pharmaceutical Preparations
Maintenance
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{fb33d7fbd87d4bc185bf02d37615a519,
title = "Atrial fibrillation and the expanding role of catheter ablation: Do antiarrhythmic drugs have a future?",
abstract = "The main therapeutic strategies for treating atrial fibrillation include rate control, maintenance of sinus rhythm, and antiembolic treatment. Current antiarrhythmic drugs are effective in about 50{\%} of patients and are often associated with adverse effects. Multiple trials suggest that rate control with proper anticoagulation treatment is associated with a similar prognosis to a more aggressive rhythm control strategy. Catheter ablation of atrial fibrillation has success rates that exceed currently available antiarrhythmic drugs. However, catheter ablation is an evolving technique that can result in complications. In some patients, antiarrhythmic drugs are still required following ablation. New antiarrhythmic drug strategies include developing drugs that are more atrial selective, alteration of the multichannel blocking agent, amiodarone, or the development of drugs with novel mechanisms of action such as gap junction facilitation of conduction. Although catheter ablation procedures will continue to grow, the millions of atrial fibrillation patients who will require therapy will continue to make antiarrhythmic drug therapy an important part of our ongoing therapeutic armamentarium.",
author = "Gerald Naccarelli and Mario Gonzalez",
year = "2008",
month = "9",
day = "1",
doi = "10.1097/FJC.0b013e318175dd73",
language = "English (US)",
volume = "52",
pages = "203--209",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Atrial fibrillation and the expanding role of catheter ablation

T2 - Do antiarrhythmic drugs have a future?

AU - Naccarelli, Gerald

AU - Gonzalez, Mario

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The main therapeutic strategies for treating atrial fibrillation include rate control, maintenance of sinus rhythm, and antiembolic treatment. Current antiarrhythmic drugs are effective in about 50% of patients and are often associated with adverse effects. Multiple trials suggest that rate control with proper anticoagulation treatment is associated with a similar prognosis to a more aggressive rhythm control strategy. Catheter ablation of atrial fibrillation has success rates that exceed currently available antiarrhythmic drugs. However, catheter ablation is an evolving technique that can result in complications. In some patients, antiarrhythmic drugs are still required following ablation. New antiarrhythmic drug strategies include developing drugs that are more atrial selective, alteration of the multichannel blocking agent, amiodarone, or the development of drugs with novel mechanisms of action such as gap junction facilitation of conduction. Although catheter ablation procedures will continue to grow, the millions of atrial fibrillation patients who will require therapy will continue to make antiarrhythmic drug therapy an important part of our ongoing therapeutic armamentarium.

AB - The main therapeutic strategies for treating atrial fibrillation include rate control, maintenance of sinus rhythm, and antiembolic treatment. Current antiarrhythmic drugs are effective in about 50% of patients and are often associated with adverse effects. Multiple trials suggest that rate control with proper anticoagulation treatment is associated with a similar prognosis to a more aggressive rhythm control strategy. Catheter ablation of atrial fibrillation has success rates that exceed currently available antiarrhythmic drugs. However, catheter ablation is an evolving technique that can result in complications. In some patients, antiarrhythmic drugs are still required following ablation. New antiarrhythmic drug strategies include developing drugs that are more atrial selective, alteration of the multichannel blocking agent, amiodarone, or the development of drugs with novel mechanisms of action such as gap junction facilitation of conduction. Although catheter ablation procedures will continue to grow, the millions of atrial fibrillation patients who will require therapy will continue to make antiarrhythmic drug therapy an important part of our ongoing therapeutic armamentarium.

UR - http://www.scopus.com/inward/record.url?scp=58149263363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149263363&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318175dd73

DO - 10.1097/FJC.0b013e318175dd73

M3 - Review article

C2 - 18806600

AN - SCOPUS:58149263363

VL - 52

SP - 203

EP - 209

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -